The estimated Net Worth of Capital Management, Llc 683 is at least 14.5 百万$ dollars as of 27 April 2018. Capital 683 owns over 11,838,235 units of Onconova Therapeutics Inc stock worth over 14,503,169$ and over the last 7 years Capital sold ONTX stock worth over 0$.
Capital has made over 1 trades of the Onconova Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 11,838,235 units of ONTX stock worth 5,090,441$ on 27 April 2018.
The largest trade Capital's ever made was buying 11,838,235 units of Onconova Therapeutics Inc stock on 27 April 2018 worth over 5,090,441$. On average, Capital trades about 11,838,235 units every 0 days since 2018. As of 27 April 2018 Capital still owns at least 14,503,169 units of Onconova Therapeutics Inc stock.
You can see the complete history of Capital 683 stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 3 Columbus Cir #2205, New York, NY 10019, USA.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over 1,631,795$ worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth 51,994,589$ . The most active insiders traders include Capital, Llc Armistice Capi...、Capital Management, Llc 683、Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of 294,478$. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth 8,666$.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: